Breast Cancer Survival Rates: Statistics by Stage, Type, and Age
Written by North Editorial Staff | Clinically reviewed by Laura Morrissey, RN, BSN | Last reviewed: March 2026
Key Takeaways
Breast cancer survival rates have improved substantially over the past three decades — overall, more than 90% of women diagnosed with breast cancer today are alive five years later.
Survival varies significantly by stage at diagnosis: localized breast cancer has a 5-year relative survival rate of 99%, while distant (metastatic) disease has a rate of approximately 29%.
Subtype matters as much as stage: HER2-positive and hormone receptor-positive subtypes have better outcomes than triple-negative breast cancer, which is more aggressive and harder to treat.
Statistics describe population-level patterns, not individual outcomes. Many people with advanced breast cancer live far longer than median estimates suggest.
Early detection is the single most powerful predictor of survival — regular screening mammography beginning at age 40 is the American Cancer Society’s recommendation for average-risk women.
Clinical trials are expanding outcomes at every stage, including for metastatic disease. Access to a trial is not a last resort — it may be the most current standard of care available.
What Are Breast Cancer Survival Rates?
Breast cancer survival rates are statistics compiled from large datasets — primarily SEER (the Surveillance, Epidemiology, and End Results program maintained by the National Cancer Institute) — that track how many people with a given diagnosis are alive after a specific period of time.
The most commonly referenced figure is the 5-year relative survival rate: the percentage of people with breast cancer who are alive five years after diagnosis, compared with people of the same age and sex without cancer. A 5-year relative survival rate of 90% means that people with breast cancer are about 90% as likely to be alive five years later as those without it.
These numbers reflect past experience. The patients included in current SEER data were diagnosed and treated years ago. Today’s treatments, particularly newer targeted therapies, immunotherapies, and CDK4/6 inhibitors, have meaningfully improved outcomes, especially for metastatic disease. The statistics you’ll read here are likely to understate what is now achievable.
Breast Cancer Survival Rates by Stage
Stage at diagnosis is the strongest single predictor of breast cancer survival. The earlier the cancer is detected, the better the outcomes.
Stage 0 (In Situ)
Stage 0 breast cancer, primarily ductal carcinoma in situ (DCIS), has a 5-year relative survival rate of approximately 99%, according to SEER data. At this stage, abnormal cells are present within the milk ducts, but have not invaded surrounding breast tissue. With appropriate treatment (usually surgery, often with radiation), the vast majority of people with DCIS are cured or have the disease controlled for decades.
Stage I
Stage I breast cancer is invasive but small (typically 2 cm or less) and has not spread to lymph nodes, or has only microscopic involvement. The 5-year relative survival rate is approximately 99–100%. Stage I disease is highly treatable, and the goal of treatment is curative in nearly all cases.
Stage II
Stage II includes larger tumors (2–5 cm) or cancer that has spread to a small number of nearby lymph nodes. The 5-year relative survival rate ranges from approximately 90–99% depending on substage (IIA vs. IIB). Stage II disease is still treated with curative intent in the vast majority of patients.
Stage III
Stage III breast cancer has spread to larger numbers of lymph nodes, or directly into the chest wall or skin. The 5-year relative survival rate ranges from approximately 66–86%, depending on substage. Treatment typically involves systemic therapy (chemotherapy, targeted agents) followed by surgery and radiation. Many patients with Stage III disease achieve long-term remission or cure.
Stage IV (Metastatic)
Metastatic breast cancer (Stage IV) has spread to distant organs such as the bones, liver, lungs, or brain. The overall 5-year relative survival rate is approximately 29%, according to the American Cancer Society. However, this average obscures meaningful variation: some subtypes (particularly HER2-positive and hormone receptor-positive disease) have seen significant improvements in median survival over the past decade, with many patients living 5–10 years or longer with modern therapies. Triple-negative metastatic breast cancer continues to carry a worse prognosis, though immunotherapy combinations are changing that picture.
Importantly, Stage IV breast cancer is generally not considered curable, but it is treatable as a chronic disease in many patients. The goal shifts from cure to long-term control, quality of life, and extending survival.
Breast Cancer Survival Rates by Subtype
Subtype — determined by hormone receptor status, HER2 status, and sometimes gene expression profiling — is an independent predictor of outcomes, layered on top of stage.
Hormone Receptor-Positive (HR+) Breast Cancer
Hormone receptor-positive breast cancer — tumors that express estrogen receptors (ER+), progesterone receptors (PR+), or both — is the most common subtype, accounting for roughly 70–80% of breast cancers. These tumors generally grow more slowly and respond well to endocrine (hormone-blocking) therapy. Prognosis is generally favorable, particularly for early-stage disease.
However, HR+ breast cancer is also notable for late recurrence — some women experience relapse 10–20 years after initial diagnosis, which is why extended adjuvant endocrine therapy (5–10 years) is recommended for higher-risk early-stage cases.
HER2-Positive Breast Cancer
HER2-positive breast cancer accounts for approximately 15–20% of cases. Before targeted therapies were available, HER2-positive disease carried a worse prognosis. The development of trastuzumab (Herceptin) and subsequent HER2-directed agents transformed this subtype into one with excellent outcomes when treated appropriately. Five-year survival rates for early-stage HER2-positive disease now approach those of HR+ disease.
For metastatic HER2-positive breast cancer, agents such as pertuzumab, T-DM1 (ado-trastuzumab emtansine), and trastuzumab deruxtecan have substantially extended median survival, with some patients living 5 years or longer.
Triple-Negative Breast Cancer (TNBC)
Triple-negative breast cancer are tumors that lack estrogen receptors, progesterone receptors, and HER2 overexpression. TNBC accounts for approximately 10–15% of breast cancer cases. It is more common in younger women and in Black women, who are diagnosed with TNBC at approximately twice the rate of white women. TNBC tends to grow faster, is more likely to spread, and does not respond to endocrine therapy or HER2-directed agents.
Despite these characteristics, approximately one-third of early-stage TNBC patients achieve pathologic complete response (pCR) — meaning no remaining cancer detectable in tissue — with neoadjuvant chemotherapy, and pCR is associated with excellent long-term outcomes. The addition of immunotherapy (pembrolizumab) to chemotherapy has improved outcomes further for high-risk early-stage and metastatic TNBC.
Five-year survival rates for TNBC are lower than other subtypes, particularly at Stage II and above, but are improving with newer agents. Active participation in clinical trials is especially important for patients with TNBC, where multiple new approaches are under investigation.
Breast Cancer Survival Rates by Age
Age at diagnosis influences both outcomes and treatment considerations:
Women under 40 have a slightly lower 5-year survival than women in their 50s and 60s, partly because younger women are more likely to be diagnosed at a later stage (they are less likely to be in routine screening programs) and are more likely to have aggressive subtypes including TNBC. Younger women also face unique considerations around fertility preservation before treatment.
Women in their 40s and 50s generally have among the best outcomes, reflecting both stage at diagnosis and relatively high rates of screening mammography in this group.
Women over 70 often have favorable subtypes (HR+, HER2-negative) but may face treatment de-escalation due to comorbidities, which can affect outcomes. Shared decision-making with the oncology team is especially important in this group.
How to Interpret Survival Statistics
Survival statistics answer one question well: what happened to populations of people with this diagnosis in the past. They do not answer: what will happen to you.
A few principles for interpreting what you read:
Statistics describe populations, not individuals. The 5-year survival rate does not predict your outcome — it describes the range of outcomes in a large group. Some people do better; some do worse.
The data lags treatment. Current statistics reflect patients treated years ago. The treatments available today, including many newer targeted therapies, immunotherapies, and antibody-drug conjugates, were not available to those patients.
Median survival is not maximum survival. When you read “median survival of X years,” half of patients in the data lived longer than that, sometimes much longer.
Your specific situation matters. Tumor characteristics, genomic profile (via tests like Oncotype DX or MammaPrint), performance status, response to treatment, and access to specialized centers all influence individual outcomes in ways no population statistic can capture.
How Clinical Trials Are Changing Survival
The improvement in breast cancer survival rates over the past three decades is directly attributable to clinical trials. Every major advance — trastuzumab for HER2-positive disease, aromatase inhibitors for HR+ disease, CDK4/6 inhibitors for metastatic disease, pembrolizumab for TNBC — moved from trial to standard of care through this process.
Today, active trials are investigating next-generation antibody-drug conjugates, novel immunotherapy combinations, PARP inhibitors for BRCA-mutated disease, and approaches to overcome treatment resistance in metastatic settings. Participating in a trial is not a measure of last resort. For many patients, it is access to treatments that are not yet widely available.
If you or someone you care for has been diagnosed with breast cancer at any stage, exploring trial options through a trial finder or with your oncology team is worth doing early. Ready to see what trials may be relevant? Explore breast cancer clinical trials or start your search with North’s trial finder.
Frequently Asked Questions
What is the overall survival rate for breast cancer?
The overall 5-year relative survival rate for breast cancer in the United States is approximately 91%, according to the American Cancer Society. This reflects all stages and subtypes combined. For women diagnosed with localized (early-stage) breast cancer, the 5-year survival rate approaches 99%.
What stage of breast cancer has the best survival rate?
Stage 0 (in situ) and Stage I have the highest survival rates, with 5-year relative survival rates of approximately 99–100%. This is why early detection through regular mammography screening is so strongly recommended — identifying cancer at these stages dramatically improves outcomes.
What is the survival rate for Stage IV breast cancer?
The overall 5-year relative survival rate for Stage IV (metastatic) breast cancer is approximately 29%, according to SEER data. However, this varies significantly by subtype: HER2-positive and hormone receptor-positive Stage IV disease often has much better outcomes than this average suggests, with newer targeted therapies extending median survival for some patients to 5 years or more.
Does triple-negative breast cancer have the worst survival rate?
Among the main subtypes, triple-negative breast cancer generally has the poorest prognosis, particularly at Stage II and above. However, approximately one-third of early-stage TNBC patients achieve pathologic complete response with chemotherapy — and those patients have excellent long-term outcomes. Newer immunotherapy combinations are also improving results for high-risk early-stage and metastatic TNBC.
How are survival rates improving for breast cancer?
Survival rates have improved substantially over the past three decades due to advances in early detection (improved mammography, broader screening programs) and treatment (targeted therapies like trastuzumab for HER2-positive disease, CDK4/6 inhibitors for metastatic HR+ disease, immunotherapy for TNBC). These improvements came directly from clinical trials. Current trials investigating antibody-drug conjugates, next-generation immunotherapy, and novel targeted approaches are expected to continue this trend.
References
American Cancer Society. (2024). Breast Cancer Survival Rates. https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
National Cancer Institute, SEER Program. (2024). Cancer Stat Facts: Female Breast Cancer. https://seer.cancer.gov/statfacts/html/breast.html
Siegel, R. L., et al. (2024). Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21820
Cortés, J., et al. (2022). Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine. https://www.nejm.org/doi/10.1056/NEJMoa2203690
Schmid, P., et al. (2022). Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine. https://www.nejm.org/doi/10.1056/NEJMoa2105342
Gradishar, W. J., et al. (2024). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419